Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II randomized trial of AS703026 plus gemcitabine versus placebo plus gemcitabine in previously untreated metastatic pancreatic cancer
2009-011992-61Phase 2Completed
- Sponsor
- Merck Serono
- Start
- Aug 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in pancreatic adenocarcinoma (PDAC) and pancreatic cancer (PC) comparing AS703026 + gemcitabine with Placebo + gemcitabine (2 arms). Primary endpoints: Progression-free survival and Progression-free survival hazard ratio. Started Aug 2009; status: completed.
02
Drugs
pimasertib
03
Conditions
pancreatic adenocarcinoma (PDAC)pancreatic cancer (PC)
Beyond the preview
Go deeper on 2009-011992-61.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-011992-61.